Aurion Biotech Launches Vyznova® (neltependocel) in Japan for the Treatment of Bullous Keratopathy of the Cornea

World’s first approved allogeneic cell therapy for corneal endothelial diseaseProf. Shigeru Kinoshita, M.D., cell therapy inventor, successfully treats first patients
SEATTLE & CAMBRIDGE, Mass. & TOKYO–BUSINESS WIRE–Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced the commercial launch of Vyznova® (generic name: neltependocel) in Japan, for the treatment of bullous keratopathy of the cornea. The…
Read More…

Source: https://newshub.medianet.com.au/2024/09/aurion-biotech-launches-vyznova-neltependocel-in-japan-for-the-treatment-of-bullous-keratopathy-of-the-cornea/68561/